Video

Dr. Shore on Benefits of Immunotherapy INO-5150 in Recurrent Prostate Cancer

​Neal D. Shore, MD, FACS, discusses the potential benefits of the immunotherapy INO-5150 for patients with biochemically recurrent prostate cancer.

Neal D. Shore, MD, FACS, medical director of the Carolina Urologic Research Center, discusses the potential benefits of the immunotherapy INO-5150 for patients with biochemically recurrent prostate cancer.

In a phase 1/2, open-label, multicenter study enrolled patients with biochemically recurrent prostate cancer and treated them with INO-5150, a DNA-based immunotherapy. This agent targets prostate-specific antigen and prostate-specific membrane antigen and was previously examined with or without plasmid-encoded cytokine adjuvant IL-12 (INO-9012). When it comes to recurrent prostate cancer, it is important to have options available, says Shore. Now, patients may have the option of receiving a daily pill rather than a required intramuscular or subcutaneous injection. This route of administration allows for patients to avoid a mandated trip to the hospital to receive the therapy, along with all the risks associated with COVID-19. 

The ability to take a once-daily pill is very convenient for patients, adds Shore. When a clinical evaluation is appropriate, then patients can met with their urologist, medical oncologist, or radiation oncologist. Overall, this kind of option provides patients with tremendous flexibility, and thus, it is a breakthrough in the treatment armamentarium for this patient population, concludes Shore.

Related Videos
Howard S. Hochster, MD, FACP,
John H. Strickler, MD
Brandon G. Smaglo, MD, FACP
Cedric Pobel, MD
Ruth M. O’Regan, MD
Michael R. Grunwald, MD, FACP
Peter Forsyth, MD
John N. Allan, MD
Dr Dorritie on the Clinical Implications of the 5-Year Follow-Up Data From CAPTIVATE in CLL/SLL
Minoo Battiwalla, MD, MS